The effect of L-arginine supplementation on the levels of antioxidative enzymes and inflammatory factors in patients with Metabolic dysfunction-associated steatotic liver disease(MASLD)

Determining the effect of L-arginine supplementation on inflammatory factors and oxidative stress indices in people with steatotic liver disease associated with metabolic disorders (MASLD)

A clinical trial with a control group, with parallel groups, double-blind, randomized. The sample size was 17 people in each group, including attrition: 22 people in each group. The data were analyzed using SPSS ver 19.

This study is a randomized double-blind controlled clinical trial on patients with metabolic disorder associated with steatotic liver disease (MASLD) referred to Razi Hospital and specialized clinics affiliated to Tehran University of Medical Sciences, which in a time interval It will be held in the fall of 1403 to the summer of 1404 in Tehran. Patients will be included in the study after being diagnosed by a specialist doctor from the Gastroenterology Clinic of Razi Hospital in terms of inclusion and non-inclusion criteria.

1) Patients with metabolic disorders associated with diagnosed steatotic liver disease without fibrosis and cap score below 310 and Metavir score below f1, which has been approved by a gastroenterologist 2) Age 30-55 3) BMI 25-35

the intervention group will consume 3000 mg of arginine daily for 8 weeks. The arginine tablets are purchased from Karen B. All patients will be monitored for pill consumption with a daily checklist and recall messages

Glutathione peroxidase (GPX), Superoxide dismutase (SOD), C-reactive protein (CRP), Erythrocyte Sedimentation Rate (ESR)

The study subjects will be divided into blocks based on gender and BMI and then will be randomly divided into two intervention groups with arginine and placebo. 44 subjects will be randomly assigned using the RAS statistical software ) (size 4) will be assigned to intervention and placebo groups, and patients will be placed in blocks of 4 based on BMI and gender. In this study, the participants are randomly placed in two intervention and placebo groups so that researchers can compare different treatments. Researchers and participants cannot arbitrarily play a role in assigning people to groups. Random allocation of people to the intervention or placebo group will be done by an experienced expert.

All subjects and researchers will be unaware of the existing grouping until the end of the study, and L-arginine supplement and placebo will be given to subjects once every 4 weeks by another person who has no knowledge of the research process. In order to evaluate the acceptance of the patients, a checklist will be prepared and given to the patients and they will be asked to record their daily consumption in it. In addition, in order to ensure the consumption of supplements, reminder messages will be sent to all patients every day